FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention describes sustained-release tablets comprising (Z)-2-butenedioate of (R)-5,6-dihydro-5- (methylamino)-4H-imidazo-[4,5-ij] -quinolin-2(1H)-one that provide administration of (Z)-2-butenedioate of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij] -quinolin-2(1H)-one (1: 1) twice per a day for treatment of patient suffering with Parkinson's disease. Invention provides precise dosing and frequency of administration of the preparation. EFFECT: valuable properties of tablet. 13 cl
